- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 128
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
- Interventions
- VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Cleveland, Ohio
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
- Interventions
- VV1, Cemiplimab
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more
- Conditions
- Multiple Sclerosis
- Interventions
- Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Colorectal Carcinoma, Metastases
- Interventions
- Ad.hIFN-β (BG00001, IDEC-201)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 2
- States / cities
- La Jolla, California • Dallas, Texas
- Conditions
- Multiple Sclerosis, Immune System Diseases
- Interventions
- ocrelizumab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Dermatomyositis, Polymyositis
- Interventions
- Dazukibart
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- Glendale, Arizona • Frisco, Texas • Houston, Texas + 1 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Fingolimod, Disease Modifying therapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 122
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more
- Conditions
- Malignant Solid Tumour
- Interventions
- VSV-IFNβ-NIS, VSV-IFNβ-NIS and avelumab
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Miami, Florida • Minneapolis, Minnesota • Columbus, Ohio + 3 more
- Conditions
- Multiple Sclerosis
- Interventions
- Avonex (Interferon beta 1a), Riluzole, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Interferon-1beta (Betaseron, BAY86-5046)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more
- Conditions
- Multiple Sclerosis, Covid19
- Interventions
- Not listed
- Lead sponsor
- St. Barnabas Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Livingston, New Jersey
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
- Interventions
- Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- BIIB017 (peginterferon beta-1a), Interferon beta type 1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia
- Conditions
- Multiple Sclerosis
- Interventions
- Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Ulcerative Colitis
- Interventions
- AVONEX
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Interferon beta-1b, Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 3 more
- Conditions
- Myositis
- Interventions
- PF-06823859, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 45
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Rebif®, Copaxone®
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Multiple Sclerosis
- Interventions
- Diroximel Fumarate, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
- Drug · Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 1,178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Eden Prairie, Minnesota
- Conditions
- Ovarian Cancer
- Interventions
- MSC-INFβ, Questionnaires
- Genetic · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- peginterferon beta-1a, Rebif
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib, Nivolumab, Multigated Acquisition Scan, Echocardiography Test, Bone Marrow Aspiration
- Procedure · Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota